Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zeria Pharmaceutical CoTSE:4559 +1.61%85 Days Payable is 71.49 as of Mar. 2026, which is 73% above its 10-year median of 41.34. GuruFocus rates TSE:4559 with a GF Score™ of 85/100 and a GF Value™ of 円2,506.68 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 925 Drug Manufacturers companies, Zeria Pharmaceutical Co ranks worse than 61.73% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zeria Pharmaceutical Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zeria Pharmaceutical Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zeria Pharmaceutical Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Zeria Pharmaceutical Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Zeria Pharmaceutical Co's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zeria Pharmaceutical Co (TSE:4559) has a Days Payable of 71.49 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zeria Pharmaceutical Co and its competitors. This is 73% above median its historical median of 41.34. Over the past decade, Zeria Pharmaceutical Co's Days Payable has ranged from 36.74 to 69.77. According to the industry distribution chart, Zeria Pharmaceutical Co ranks #571 out of 925 companies in the Drug Manufacturers industry, placing it in the top 61.7%.
Is Zeria Pharmaceutical Co's Days Payable too high?
Zeria Pharmaceutical Co's current Days Payable of 71.49 is 73% above median its 10-year median of 41.34. Over the past 10 years, this metric has ranged from a low of 36.74 to a high of 69.77. The Drug Manufacturers industry median Days Payable is 90.38. Zeria Pharmaceutical Co's value of 71.49 is 20.9% below this industry median. Based on the distribution chart, Zeria Pharmaceutical Co ranks #571 out of 925 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Zeria Pharmaceutical Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zeria Pharmaceutical Co's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Zeria Pharmaceutical Co ranks #571 out of 925 companies for Days Payable. This places Zeria Pharmaceutical Co in the lower half of its industry. The industry median Days Payable is 90.38. Zeria Pharmaceutical Co's value of 71.49 is 20.9% below this benchmark. Historically, Zeria Pharmaceutical Co's own Days Payable has ranged from 36.74 to 69.77 over the past decade. While the company's 10-year median is 41.34 vs. the industry median of 90.38, Zeria Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zeria Pharmaceutical Co's current Days Payable of 71.49 is 20.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zeria Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zeria Pharmaceutical Co's current Days Payable is 71.49, which is 73% above median its own 10-year median of 41.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zeria Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zeria Pharmaceutical Co (TSE:4559) is currently considered Modestly Undervalued. The stock's GF Value™ is 円2,506.68, compared to a current price of 円2,087.00 — trading 16.7% below its estimated fair value. The current Days Payable is 71.49, which is 73% above median its 10-year median of 41.34 and 20.9% below the Drug Manufacturers industry median of 90.38. Zeria Pharmaceutical Co's overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Zeria Pharmaceutical Co (TSE:4559), the current Days Payable is 71.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zeria Pharmaceutical Co (TSE:4559) Overvalued in 2026?
Based on GuruFocus' analysis, Zeria Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円2,087.00 is trading 16.7% below its estimated GF Value™ of 円2,506.68.
GuruFocus considers Zeria Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for TSE:4559:
Days Payable: 71.49 (73% above median its 10-year median of 41.34)
GF Value™: 円2,506.68 vs. price of 円2,087.00 (16.7% below fair value)
Industry Position: 20.9% below the Drug Manufacturers median (#571 of 925)
No single metric tells the full story. See the TSE:4559 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zeria Pharmaceutical Co Ltd is a Japanese pharmaceutical company. The company through its subsidiaries engages in two business divisions which include ethical pharmaceutical products and consumer healthcare products business division. It principally manufactures, sells, imports and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, reagents, cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, and health equipment.
85GF Score
Get the complete analysis for TSE:4559
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4559 has been successfully added to your 
